Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medtronic plc (NYSE: MDT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, giving investors and analysts a detailed view of its financial condition, capital structure, governance, and material events. As an issuer with ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, Medtronic files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A, and specialized forms such as Form 25 for the removal from listing of specific debt securities.
Medtronic’s Form 8-K filings cover topics such as quarterly financial results, debt offerings, redemptions of senior notes, amendments to its Memorandum and Articles of Association, changes in board composition and executive roles, and other material definitive agreements. For example, recent 8-Ks describe euro-denominated senior notes due 2030 and 2045, their guarantees by Medtronic plc and affiliates, and the use of proceeds to repay existing notes. Other current reports document National Coverage Determinations, financial guidance updates, and dividend-related actions referenced in company news releases.
The company’s proxy statements (DEF 14A) outline its corporate governance structure, director elections, executive compensation programs, and shareholder proposals, including amendments to Articles of Association and capital reduction measures under Irish law. Form 25 filings relate to the delisting of specific classes of guaranteed senior notes once they are redeemed or otherwise withdrawn from the exchange, and do not affect the listing of MDT ordinary shares.
On this page, Stock Titan pairs Medtronic’s filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand items such as new debt issuances, changes in capital structure, or governance amendments. You can review 10-K and 10-Q reports for segment performance and risk disclosures, scan 8-Ks for notable events, and monitor registration statements and S-1 filings, such as the proposed IPO of the MiniMed diabetes business, to follow Medtronic’s strategic and financial decisions over time.
Medtronic announced a significant board expansion and appointment in an 8-K filing dated June 28, 2025. The Board of Directors increased from 10 to 11 members with the appointment of Dr. Joon Lee, effective June 18, 2025.
Key details of the appointment:
- Dr. Lee will serve on the Science and Technology Committee and the Compensation and Talent Committee
- Will receive standard non-employee director compensation including annual cash retainer and equity grants as outlined in the August 2024 proxy statement
- No special arrangements or understandings influenced the appointment
- No reportable transactions under Item 404(a) of Regulation S-K between Dr. Lee or immediate family and the company
The appointment was formally announced via press release on June 23, 2025. The filing was executed by Ivan K. Fong, Executive Vice President, General Counsel and Secretary.
Medtronic plc (MDT) has delivered a routine notice to the U.S. Securities and Exchange Commission stating that its Annual Report on Form 10-K for the fiscal year ended April 25, 2025, filed on June 20, 2025, contains disclosure made under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act. The letter, signed by Vice President, Global Controller and Chief Accounting Officer Denise L. Blomquist, fulfills the statutory requirement to alert the SEC of any Iran-related activities discussed in the 10-K. No quantitative details or descriptions of the underlying transactions are provided in this notice, leaving investors to consult the full 10-K for specifics.
Medtronic filed its FY2025 10-K report, detailing operations across four major segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company maintains a strong international presence with significant operations in both US and international markets.
Key operational highlights include:
- Strategic focus on enterprise excellence and simplification restructuring programs
- Continued investment in research and development across all segments
- Notable divestiture of the Ventilator Product Line in February 2024
- Completion of the Renal Care Solutions/Mozarc transaction in April 2023
Financial structure includes various senior notes due between 2025-2053 with interest rates ranging from 0% to 4.15%. The company maintains a diversified debt portfolio in multiple currencies (USD, EUR, JPY). Significant emphasis on fair value measurements and risk management, particularly in Level 3 assets including revenue and product development milestones.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
